Skip to main content
. 2022 Nov 10;13:953210. doi: 10.3389/fimmu.2022.953210

Figure 2.

Figure 2

Forest plot depicts a comparison of the incidence of CMV infection among LT recipients undergoing antiviral prophylaxis and preemptive therapy.